Upper Gingival Squamous Cell Carcinoma Clinical Trial
Official title:
Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms in Cetuximab Activity Used in Palliative Treatment of Upper Aerodigestive Tract Tumours
Hypothesis:
Cetuximab, an anti-EGFR antibody, is used with radiotherapy in the treatment of locally
advanced and inoperable upper aerodigestive tract cancers. Actually, no predictive
biomarkers of Cetuximab antitumor activity are known in this setting. It has been shown
recently that FCγRIIIA and FCγRIIA receptor polymorphisms played a role in antitumor
activity of trastuzumab and cetuximab.
The investigators therefore hypothesized that FCγRIIIA and FCγRIIA receptor polymorphisms
may play a predictive role in Cetuximab effectiveness in upper aerodigestive tract cancers
with recurrence or metastatic disease that make them inaccessible to loco regional
treatment.
Hypothesis:
Cetuximab, an anti-EGFR antibody, is used with radiotherapy in the treatment of locally
advanced and inoperable upper aerodigestive tract cancers. Actually, no predictive
biomarkers of Cetuximab antitumor activity are known in this setting. It has been shown
recently that FCγRIIIA and FCγRIIA receptor polymorphisms played a role in antitumor
activity of trastuzumab and cetuximab.
We therefore hypothesized that FCγRIIIA and FCγRIIA receptor polymorphisms may play a
predictive role in Cetuximab effectiveness in upper aerodigestive tract cancers with
recurrence or metastatic disease that make them inaccessible to loco regional treatment.
This study is a multicentre prospective pharmacogenetic observational study, conducted on
locally advanced and inoperable upper aerodigestive tract cancers.
;
N/A